tbuckley/cabot-search huggingface dataset:
Abstract 3603: Optimizing combination therapy against antiestrogen-resistance in estrogen receptor positive breast cancer
Authors: Lauren M. Gutgesell, Rui Xiong, Jiong Zhao, Debra A. Tonetti, Gregory R. Thatcher
Journal: Cancer Research (2017)

Abstract Approximately 75% of breast cancer incidences are Estrogen Receptor positive (ER+). Treatment of ER+ breast cancer with antiestrogen endocrine therapy targets the proliferative mechanisms of ER using selective ER modulators (SERMs), such as tamoxifen, and selective ER downregulators (SERDs), such as fulvestrant. The resistance to endocrine therapy, either innate or acquired, is clinically diagnosed in up to 50% of patients within 5 years of treatment. Antiestrogen therapy of ER+ mammary cancer cells in vitro and in xenografts does not cause complete cell death or regression. Through the use of combination therapy to target the remaining sub-population of cells, complete regression can be predicted. Our lab has developed endocrine tamoxifen-resistant models through prolonged exposure to tamoxifen, estrogen deprivation, and overexpression of PKCα, a pro-survival pathway component, in addition to a fulvestrant-resistant model through prolonged exposure to fulvestrant. Investigation of the resistance mechanisms will provide insight into potential, combinatorial targets for overcoming endocrine resistance in ER+ breast cancer. Use of spheroidal 3D cell culture provides a physiologically relevant model with sufficient throughput for drug discovery. Establishing spheroids and subsequent treatment predicts the efficacy of combination treatment on tumor regression. Targeting pathways associated with increased prevalence of resistance, such as CDK 4/6, can be employed for clinical therapy. Using both novel in-house and clinical SERMs and SERDs, we have used these multiple cell lines to discover combinatorial targets using both mechanistic and unbiased screening approaches. The use of combination endocrine therapy in tamoxifen-resistant models has shown antiproliferative synergy, and is able to enhance tumor regression in xenografts. By optimizing combinatorial endocrine treatment against both fulvestrant- and tamoxifen-resistance, novel therapeutic approaches are being developed for ER+ breast cancer. Citation Format: Lauren M. Gutgesell, Rui Xiong, Jiong Zhao, Debra A. Tonetti, Gregory R. Thatcher. Optimizing combination therapy against antiestrogen-resistance in estrogen receptor positive breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 3603. doi:10.1158/1538-7445.AM2017-3603
Abstract 16743: Muscle Skeletal Receptor Tyrosine-Protein Kinase (MuSK) is Associated With Low Density Lipoprotein Levels in Diabetic Patients on Statins Without Prior Cardiovascular Disease: A Proteomic Analysis of FACTOR-64 Clinical Trial Subjects
Authors: Stacey Knight, Bryce Christensen, Viet T Le, Heidi T May, Jeffrey L Anderson, Kirk U Knowlton, Joseph B Muhlestein
Journal: Circulation (2017)

Introduction: There is interest in discovering new pathways that can help reduce low density lipoprotein cholesterol (LDL-C), especially in patients already on statins that haven’t achieved LDL-C g...
The Association of Late-Life Diabetes Status and Hyperglycemia With Incident Mild Cognitive Impairment and Dementia: The ARIC Study
Authors: Andreea M. Rawlings, A. Richey Sharrett, Marilyn S. Albert, Josef Coresh, B. Gwen Windham, Melinda C. Power, David S. Knopman, Keenan Walker, Sheila Burgard, Thomas H. Mosley, Rebecca F. Gottesman, Elizabeth Selvin
Journal: Diabetes Care (2019)

OBJECTIVE We sought to examine associations in older adults among diabetes, glycemic control, diabetes duration, and biomarkers of hyperglycemia with incident mild cognitive impairment (MCI) and incident dementia. RESEARCH DESIGN AND METHODS We conducted a prospective analysis of 5,099 participants from the Atherosclerosis Risk in Communities (ARIC) Study who attended the fifth (2011–2013) exam. Cognitive status was assessed during follow-up via telephone calls, death certificate codes, surveillance, and a follow-up examination (2016–2017). We defined incident cognitive impairment as incident MCI or incident dementia in persons dementia-free at the index examination; we also examined each outcome separately. Diabetes was defined using self-report, medications, or HbA1c ≥6.5%; poor glycemic control in persons with diabetes was defined as HbA1c ≥7%. We examined the following biomarkers of hyperglycemia: HbA1c, fructosamine, glycated albumin, and 1,5-anhydroglucitol. RESULTS Mean age at baseline was 76 years, 59% were female, and 21% were black. Diabetes (hazard ratio [HR] 1.14 [95% CI 1.00, 1.31]), poor glycemic control in persons with diabetes (HR 1.31 [95% CI 1.05, 1.63]), and longer diabetes duration (≥5 vs. &amp;lt;5 years; HR 1.59 [95% CI 1.23, 2.07]) were significantly associated with incident cognitive impairment. We found a J-shaped association between HbA1c and incident dementia. Glycated albumin and fructosamine were also associated with incident dementia, independently of HbA1c. HbA1c and fructosamine were also associated with incident MCI. CONCLUSIONS Diabetes status, poor glycemic control, and longer diabetes duration were associated with worse cognitive outcomes over a median follow-up of 5 years.
Pervasive H3K27 Acetylation Leads to ERV Expression and a Therapeutic Vulnerability in H3K27M Gliomas
Authors: Brian Krug, Nicolas De Jay, Ashot S. Harutyunyan, Shriya Deshmukh, Dylan M. Marchione, Paul Guilhamon, Kelsey C. Bertrand, Leonie G. Mikael, Melissa K. McConechy, Carol C.L. Chen, Sima Khazaei, Robert F. Koncar, Sameer Agnihotri, Damien Faury, Benjamin Ellezam, Alexander G. Weil, Josie Ursini-Siegel, Daniel D. De Carvalho, Peter B. Dirks, Peter W. Lewis, Paolo Salomoni, Mathieu Lupien, Cheryl Arrowsmith, Paul F. Lasko, Benjamin A. Garcia, Claudia L. Kleinman, Nada Jabado, Stephen C. Mack
Journal: Cancer Cell (2019)
IS ENDOSCOPIC BALLOON DILATION STILL ASSOCIATED WITH HIGHER RATES OF PANCREATITIS? A COMPREHENSIVE SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: C Ogawa Matsubayashi, W Marques Bernardo, A Coutinho Madruga, RC Lins Mota, M Oliveira de Marco, D Tavares Rezende, V Ottoboni Brunaldi, T Prince Franzini, E Guimarães Hourneaux de Moura
Journal: Endoscopy (2019)

Evaluate effectiveness and safety of endoscopic balloon dilation compared with sphincterotomy or with endoscopic balloon dilation plus sphincterotomy in patients with common bile duct stones.
Stimulation of growth of prostate cancer cells 22Rv1 through activation of the signaling pathways of p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase
Authors: Hannes Steiner, Sonia Godoy-Tundidor, Ilaria T. Cavarretta, Dietmar Fuchs, Matthias Fiechtl, Katrin Friedbichler, Georg Bartsch, Alfred Hobisch, Zoran Culig
Journal: Cancer Research (2005)

991  Interleukin-6 (IL-6), a pleiotropic regulator of prostate cancer cell proliferation and apoptosis, and oncostatin M (OSM), an IL-6-type cytokine, affect the growth of prostate cancers in a paracrine and autocrine manner. In order to understand better the mechanisms controling proliferation and intracellular signaling by these cytokines in advanced prostate carcinoma, we performed studies in 22Rv1 cells derived from the relapsed xenograft CWR22R. Expression of IL-6 and OSM receptors and elements of signal transduction pathways in 22Rv1 cells were investigated by RT-PCR. IL-6 secretion was measured in conditioned medium from 22Rv1 cells by ELISA. Expression and phosphorylation of signal transducers and activators of transcription factor (STAT) 3, mitogen-activated protein kinases p44/p42 and p38, and Akt was investigated by Western blot. 22Rv1 cells express both subunits of the IL-6 receptor (gp80 and gp130) and leukemia inhibitory factor receptor-β but not OSM receptor-β. IL-6 was not detectable in conditioned medium from 22Rv1 cells. Their proliferation was stimulated by exogenous IL-6 or OSM and the maximal effect was observed at a concentration of 10 ng/ml of either cytokine. Neither IL-6 nor OSM induced phosphorylation of STAT3 or p44/p42 kinases. Both cytokines increased Akt phosphorylation. In addition, OSM showed a modest stimulatory effect on p38 phosphorylation. IL-6 and OSM stimulate proliferation of 22Rv1 cells, at least in part through activation of the phosphatidylinositol 3-kinase signaling pathway. Our data provide additional evidence for the growth-stimulatory role of IL-6 and related cytokines in advanced prostate cancer and may serve as a basis for the development of novel experimental therapies.
OUTCOME OF ENDOSCOPIC BALLOON DILATATION FOR SMALL BOWEL STRICTURES USING SINGLE-BALLOON ENTEROSCOPY IN PATIENTS WITH CROHN'S DISEASE
Authors: SN Hong, MJI Goh, ER Kim, DK Chang, YH Kim
Journal: Endoscopy (2019)

Long standing and relapsing nature of CD, frequent surgeries should be avoided in order to reduce the risk of short bowel syndrome. Endoscopic balloon dilatation (EBD) in CD is minimally invasive bowel-length preserving method. Although most of strictures in CD were occurred in small bowels, a few small studies for the balloon-assisted enteroscopic balloon dilatation for small bowel strictures in patients with CD was reported. We evaluated the outcome of EBD for small bowel strictures using single-balloon enteroscopy (SBE) in patients with CD.
Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial
Authors: Peng-Peng Xu, Di Fu, Jian-Yong Li, Jian-Da Hu, Xin Wang, Jian-Feng Zhou, Hao Yu, Xia Zhao, Yao-Hui Huang, Lu Jiang, Feng Liu, Li-Ping Su, Zhuo-Wen Chen, Qing-Shu Zeng, Jie-Ping Chen, Mei-Yun Fang, Jun Ma, Ting Liu, Yong-Ping Song, Kang Yu, Yan Li, Lu-Gui Qiu, Xie-Qun Chen, Jian Gu, Jin-Song Yan, Ming Hou, Heng-Ye Huang, Li Wang, Shu Cheng, Yang Shen, Hui Xiong, Sai-Juan Chen, Wei-Li Zhao
Journal: The Lancet Haematology (2019)
HISTOPATHOLOGICAL FEATURES OF POSTCOLONOSCOPY COLORECTAL CANCER
Authors: V Sastre Lozano, S Morán Sánchez, J García Solano, P Conesa Zamora, G Ruiz Merino
Journal: Endoscopy (2019)

The targets of this study are to describe postcolonoscopy colorectal cancer (PCCRC) histopathological features and to evaluate relevant differences between PCCRC and sporadic colorectal cancer (SCRC) in this topic.
EFFECTS OF THE RESPECT OF EDUCATIONAL PATIENT MESSAGES BEFORE COLONOSCOPY ON BOWEL PREPARATION
Authors: E Bel Hadj Mabrouk, Y Zaimi, M Ayari, S Ayadi, L Mouelhi, R Dabbeche
Journal: Endoscopy (2019)

Adequate bowel preparation is essential for a successful endoscopy for screening as well as surveillance. Despite patients' educational oral or written messages, inadequate bowel preparation remains high.
C9ORF72-ALS/FTD-associated poly(GR) binds Atp5a1 and compromises mitochondrial function in vivo
Authors: So Yoen Choi, Rodrigo Lopez-Gonzalez, Gopinath Krishnan, Hannah L. Phillips, Alissa Nana Li, William W. Seeley, Wei-Dong Yao, Sandra Almeida, Fen-Biao Gao
Journal: Nature Neuroscience (2019)
Viremia Trajectories of HIV in HIV-Positive Women in the United States, 1994-2017
Authors: Seble G. Kassaye, Cuiwei Wang, Joanne Michelle F. Ocampo, Tracey E. Wilson, Kathryn Anastos, Mardge Cohen, Ruth M. Greenblatt, Margaret A. Fischl, Igho Otofukun, Adaora Adimora, Mirjam-Colette Kempf, Gerald B. Sharp, Mary Young, Michael Plankey
Journal: JAMA Network Open (2019)

<h3>Importance</h3> Viral suppression of HIV is an important treatment goal to decrease morbidity, mortality, and risk of transmission to others. <h3>Objective</h3> To characterize longitudinal HIV viral load outcomes among women enrolled in the Women's Interagency HIV Study (WIHS). <h3>Design, Setting, and Participants</h3> A prospective cohort study of HIV-positive women with semiannual study visits and a minimum of 5 follow-up visits was conducted from 1994 to 2017. The WIHS sites included in this analysis are in Brooklyn and Bronx, New York; Chicago, Illinois; San Francisco, California; and Washington, DC. <h3>Main Outcomes and Measures</h3> Women were categorized into groups based on their probability of achieving viral load suppression below 200 copies/mL using logistic trajectory modeling. Multinomial regression analysis was used to identify factors associated with placement in the group with the highest probability of viremia. <h3>Results</h3> At baseline, the mean (SD) age of the 1989 women was 36.9 (8.0) years, mean CD4<sup>+</sup>T-lymphocyte count was 467/mm<sup>3</sup>, median (interquartile range) HIV RNA was 6200.0 (384.5-41 678.0) copies/mL, and 1305 women (65.6%) were African American. Three trajectory groups were identified with low (568 [28.6%]), intermediate (784 [39.4%]), and high (637 [32.0%]) probability of viremia above 200 copies/mL. The mean (SD) cumulative years of viral suppression were 18.7 (4.0) years, 12.2 (3.1) years, and 5.8 (2.9) years in the respective groups. Factors associated with high probability of viremia included younger age (odds ratio [OR]. 0.99; 95% CI, 0.98-0.99;<i>P</i> = .03), African American race (odds ratio [OR], 2.43; 95% CI, 1.75-3.37),<i>P</i> &lt; .001), Hispanic race/ethnicity (OR, 1.50; 95% CI, 1.03-2.19;<i>P</i> = .04), increased levels of depressive symptoms (OR, 1.17; 95% CI, 1.01-1.36;<i>P</i> = .03), drug use (OR, 1.23; 95% CI, 1.01-1.51;<i>P</i> = .04), lower CD4+ T-lymphocyte counts (OR, 95% CI, 0.82; 0.80-0.85;<i>P</i> &lt; .001), and unstable housing (OR, 1.25, 95% CI, 1.03-1.50;<i>P</i> = .02). Between 2015 and 2017, 71.2% of women demonstrated sustained viral suppression: 89.6% (310 of 346) of those with low viremia, 83.4% (346 of 415) with intermediate, and 35.2% (112 of 318) with high probability of viremia. <h3>Conclusions and Relevance</h3> This longitudinal approach suggested that the probability of viremia decreased substantially over time for most participants, including among women with earlier histories of incomplete viral suppression. The findings from this study suggest that continued efforts are needed to address mental health, social, behavioral and structural factors that were identified as associated with high probability of HIV viremia over time.
ENDOSCOPIC SUBMUCOSAL DISSECTION IN LARGE RECTAL ADENOMAS AND EARLY CANCER: INITIAL RESULTS IN A BICENTRIC SERIES
Authors: D de Frutos, B Conde, B Agudo, M Hernández, M López, CE González, J Santiago, I González Partida, M González-Haba, A Garrido, P Matallanos, E Blazquez, M Bote, M Sol Delgado, P García, JL Calleja, A Herreros de Tejada
Journal: Endoscopy (2019)

To evaluate ESD for the treatment of large rectal adenomas and early cancer (LRAEC) in two Spanish centers.
Effect of Restriction of the Number of Concurrently Open Records in an Electronic Health Record on Wrong-Patient Order Errors
Authors: Jason S. Adelman, Jo R. Applebaum, Clyde B. Schechter, Matthew A. Berger, Stan H. Reissman, Raja Thota, Andrew D. Racine, David K. Vawdrey, Robert A. Green, Hojjat Salmasian, Gordon D. Schiff, Adam Wright, Adam Landman, David W. Bates, Ross Koppel, William L. Galanter, Bruce L. Lambert, Susan Paparella, William N. Southern
Journal: JAMA (2019)

Recommendations in the United States suggest limiting the number of patient records displayed in an electronic health record (EHR) to 1 at a time, although little evidence supports this recommendation.To assess the risk of wrong-patient orders in an EHR configuration limiting clinicians to 1 record vs allowing up to 4 records opened concurrently.This randomized clinical trial included 3356 clinicians at a large health system in New York and was conducted from October 2015 to April 2017 in emergency department, inpatient, and outpatient settings.Clinicians were randomly assigned in a 1:1 ratio to an EHR configuration limiting to 1 patient record open at a time (restricted; n = 1669) or allowing up to 4 records open concurrently (unrestricted; n = 1687).The unit of analysis was the order session, a series of orders placed by a clinician for a single patient. The primary outcome was order sessions that included 1 or more wrong-patient orders identified by the Wrong-Patient Retract-and-Reorder measure (an electronic query that identifies orders placed for a patient, retracted, and then reordered shortly thereafter by the same clinician for a different patient).Among the 3356 clinicians who were randomized (mean [SD] age, 43.1 [12.5] years; mean [SD] experience at study site, 6.5 [6.0] years; 1894 females [56.4%]), all provided order data and were included in the analysis. The study included 12 140 298 orders, in 4 486 631 order sessions, placed for 543 490 patients. There was no significant difference in wrong-patient order sessions per 100 000 in the restricted vs unrestricted group, respectively, overall (90.7 vs 88.0; odds ratio [OR], 1.03 [95% CI, 0.90-1.20]; P = .60) or in any setting (ED: 157.8 vs 161.3, OR, 1.00 [95% CI, 0.83-1.20], P = .96; inpatient: 185.6 vs 185.1, OR, 0.99 [95% CI, 0.89-1.11]; P = .86; or outpatient: 7.9 vs 8.2, OR, 0.94 [95% CI, 0.70-1.28], P = .71). The effect did not differ among settings (P for interaction = .99). In the unrestricted group overall, 66.2% of the order sessions were completed with 1 record open, including 34.5% of ED, 53.7% of inpatient, and 83.4% of outpatient order sessions.A strategy that limited clinicians to 1 EHR patient record open compared with a strategy that allowed up to 4 records open concurrently did not reduce the proportion of wrong-patient order errors. However, clinicians in the unrestricted group placed most orders with a single record open, limiting the power of the study to determine whether reducing the number of records open when placing orders reduces the risk of wrong-patient order errors.clinicaltrials.gov Identifier: NCT02876588.
Response to Comment on Davis et al. Development and Validation of a Simple Hip Fracture Risk Prediction Tool for Type 2 Diabetes: the Fremantle Diabetes Study Phase I. Diabetes Care 2018;42:102–109
Authors: Wendy A. Davis, Emma J. Hamilton, David G. Bruce, Timothy M.E. Davis
Journal: Diabetes Care (2019)

Bůžkova and Barzilay (1) question the absence of cognitive impairment and an elevated urinary albumin-to-creatinine ratio (ACR) from our Fremantle Diabetes Study (FDS) hip fracture risk equation for type 2 diabetes (2). The four supporting references they cite relate to studies in subsets of the general population (one a meta-analysis of the prevalence of dementia in hip fracture patients, and the three others in older people aged ≥65 years in whom both hip fractures and dementia are common). This contrasts with our equation, which was developed from longitudinal data derived from a cohort of well-characterized community-based people with type 2 diabetes with a wide age range (2). As we …
Recombinant Human Soluble Thrombomodulin in Patients With Sepsis-Associated Coagulopathy
Authors: Tom van der Poll
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ENDOSCOPIC SUBMUCOSAL DISSECTION (ESD) FOR EARLY BARRETT'S NEOPLASIA – IS AGE A BARRIER?
Authors: S Arndtz, S Subramaniam, E Hossain, M Abdelrahim, P Bhandari
Journal: Endoscopy (2019)

ESD is an established therapeutic option for early neoplasia, however it is thought to carry a higher complication rate. The aim of our study was to evaluate the safety and efficacy of ESD for Barrett's neoplasia in an ageing Western population.
Current treatment landscape in triple negative breast cancer: A systematic literature review
Authors: A.Z. Fu, Y. Kuang, M.S. Fazeli, N. Kumar, C. Davis
Journal: Annals of Oncology (2019)

Background: Triple negative breast cancer (TNBC) accounts for 15–20% of breast cancer diagnoses. As novel targets and therapies for TNBC emerge, a comprehensive overview of the current landscape of evidence on the approved or developing treatment options was needed. Methods: We followed Cochrane guidelines for systematic literature reviews (SLR). Population of interest was adult female patients with TNBC receiving any pharmacological treatment. Studies of interest were randomized controlled trials (RCTs) or comparative non-randomized clinical trials (non-RCTs). Outcomes included survival, disease and pathological response, and adverse events. A search from January 2003 to July 2018 was performed on MEDLINE®, Embase, the Cochrane Central Database of Controlled Trials, and the US and European clinical trials registries. Conference proceedings from ASCO, ESMO, and SABCS covering the period from 2016 to end of 2018 were also reviewed. Results: Eighty-nine publications corresponding to 77 unique trials met the eligibility criteria for this review. The 72 RCTs and 5 comparative non-RCTs were predominantly open-label phase 2 or 3 trials. Immune checkpoint inhibitors, including nivolumab, atezolizumab, durvalumab, and pembrolizumab, were evaluated in 5 trials. Targeted therapies, primarily VEGF inhibitors (n = 12) and PARP inhibitors (n = 7), were evaluated in 40 trials. Thirty-two trials evaluated chemotherapy alone, with the majority assessing chemotherapy combinations of 2 or more subclasses. Thirty-five trials reported treatments on metastatic or advanced TNBC, 31 on neoadjuvant and 11 on adjuvant therapies. Overall survival (n = 32) and progression-free survival (n = 30) were the most commonly reported efficacy outcomes. Safety outcomes were reported in 39 trials. Conclusions: Targeted therapies, followed by chemotherapy in forms of combinations of 2 or more subclasses, composed most trials in TNBC, with immunotherapy being rarely used thus far. The trials were mainly conducted in metastatic or advanced setting, followed by neoadjuvant and adjuvant settings. Comparison across different TNBC treatment options warrants further investigation as the growing evidence base evolves. Legal entity responsible for the study: Bristol-Myers Squibb. Funding: Bristol-Myers Squibb. Disclosure: A.Z. Fu, N. Kumar, C. Davis: Employee: Bristol-Myers Squibb. Y. Kuang, M.S. Fazeli: Employee: Doctor Evidence LLC.
ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY IN THE MANAGEMENT OF BILIARY COMPLICATIONS AFTER ORTHOTOPIC LIVER TRANSPLANTATION
Authors: J Egea Valenzuela, R Jijon Crespin, A Serrano Jimenez, F Alberca de las Parras
Journal: Endoscopy (2019)

Biliary complications are frequent after orthotopic liver transplantation. Management of these complications with endoscopic retrograde cholangiopancreatography (ERCP) is available. The aim of the present study was to analyze the experience in the endoscopic management of biliary complications after liver transplantation in a third level center, and to determinate the factors associated with higher rates of technical and clinical success.